Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

JGA Topic Review

Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease

Matsuoka Y. · Kanai T.

Author affiliations

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Related Articles for ""

Digestion 2013;88:17-19

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of JGA Topic Review

Published online: June 20, 2013
Issue release date: July 2013

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

It is not too much to say that infliximab has revolutionized the treatment of Crohn's disease. However, there is the problem of ‘secondary failure' wherein the effect may diminish during treatment. This is a much-discussed topic. For example, not all patients with secondary failure can maintain remission with dose intensification to 10 mg/kg. It is also important to make the appropriate drug selection and to clarify the optimal timing of dose intensification for achieving long-term maintenance of remission, including discussion of the first priority use of adalimumab.

© 2013 S. Karger AG, Basel


References

  1. Hanauer SB, Feagan BG, Lichtenstein GR, et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.
  2. Rutgeerts P, Feagan BG, Lichtenstein GR, et al: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-413.
  3. Regueiro M, Siemanowski B, Kip KE, et al: Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007;13:1093-1099.
  4. Schnitzler F, Fidder H, Ferrante M, et al: Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-center cohort. Gut 2009;58:492-500.
  5. Billioud V, Sandborn WJ, Peyrin-Biroulet L: Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-684.
  6. Maser EA, Villela R, Silverberg MS, et al: Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-1254.
  7. Hibi T, Sakuraba A, Watanabe M, et al: Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2012;18:1480-1487.
  8. Hanauer SB, Wagner CL, Bala M, et al: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in crohn's dasease. Clin Gastroenterol Hepatol 2004;2:542-553.
  9. Baert F, Noman M, Vermeire S, et al: Influence of immunogenicity on the long-term efficacy of infliximab in crohn's disease. N Engl J Med 2003;348:601-608.
  10. Takeuchi T, Miyasaka N, Tatsuki Y, et al: Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:1208-1215.
  11. Tomita K, Chiba T, Sugai T, et al: Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease. Hepato-Gastroenterology 2010;57:535-539.
  12. Chaparro M, Panes J, García V, et al: Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose ‘escalation' in patients losing response. J Clin Gastroenterol 2011;45:113-118.
  13. L. Katz, J.P. Gisbert, B. Manoogian, et al: Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Gut 2011;60(suppl 3)A71.
  14. Sandborn WJ, Rutgeerts P, Enns R, et al: Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-838.
  15. Colombel JF, Sandborn WJ, Reinisch W, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J 2010;362:1383-1395.

Article / Publication Details

First-Page Preview
Abstract of JGA Topic Review

Published online: June 20, 2013
Issue release date: July 2013

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.